» Articles » PMID: 31931009

Oncogenic K-Ras4B Dimerization Enhances Downstream Mitogen-activated Protein Kinase Signaling

Overview
Journal J Mol Biol
Publisher Elsevier
Date 2020 Jan 14
PMID 31931009
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Ras recruits and activates effectors that transmit receptor-initiated signals. Monomeric Ras can bind Raf; however, Raf's activation requires dimerization, which can be facilitated by Ras dimerization. Previously, we showed that active K-Ras4B dimerizes in silico and in vitro through two major interfaces: (i) β-interface, mapped to Switch I and effector-binding regions, (ii) α-interface at the allosteric lobe. Here, we chose constitutively active K-Ras4B as our control and two double mutants (K101D and R102E; and R41E and K42D) in the α- and β-interfaces. Two of the mutations are from The Cancer Genome Atlas (TCGA) and the Catalogue Of Somatic Mutations In Cancer (COSMIC) data sets. R41 and R102 are found in several adenocarcinomas in Ras isoforms. We performed site-directed mutagenesis, cellular localization experiments, and molecular dynamics (MD) simulations to assess the impact of the mutations on K-Ras4B dimerization and function. α-interface K101D/R102E double mutations reduced dimerization but only slightly reduced downstream phosphorylated extracellular signal-regulated kinase (ERK) (pERK) levels. While β-interface R41E/K42D double mutations did not interfere with dimerization, they almost completely blocked K-Ras4B-mediated ERK phosphorylation. Both double mutations increased downstream phosphorylated Akt (pAkt) levels in cells. Changes in pERK and pAkt levels altered ERK- and Akt-regulated gene expressions, such as EGR1, JUN, and BCL2L11. These results underscore the role of the α-interface in K-Ras4B homodimerization and the β-surface in effector binding. MD simulations highlight that the membrane and hypervariable region (HVR) interact with both α- and β-interfaces of K-Ras4B mutants, respectively, inhibiting homodimerization and probably effector binding. Mutations at both interfaces interfered with mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase signaling but in different forms and extents. We conclude that dimerization is not necessary but enhances downstream MAPK signaling.

Citing Articles

Exploring CRD mobility during RAS/RAF engagement at the membrane.

Nguyen K, Lopez C, Neale C, Van Q, Carpenter T, Di Natale F Biophys J. 2022; 121(19):3630-3650.

PMID: 35778842 PMC: 9617161. DOI: 10.1016/j.bpj.2022.06.035.


Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs.

Nussinov R, Zhang M, Maloney R, Liu Y, Tsai C, Jang H J Mol Biol. 2022; 434(17):167569.

PMID: 35378118 PMC: 9398924. DOI: 10.1016/j.jmb.2022.167569.


Ras Multimers on the Membrane: Many Ways for a Heart-to-Heart Conversation.

Ozdemir E, Koester A, Nan X Genes (Basel). 2022; 13(2).

PMID: 35205266 PMC: 8872464. DOI: 10.3390/genes13020219.


Allostery, and how to define and measure signal transduction.

Nussinov R, Tsai C, Jang H Biophys Chem. 2022; 283:106766.

PMID: 35121384 PMC: 8898294. DOI: 10.1016/j.bpc.2022.106766.


Mechanism of activation and the rewired network: New drug design concepts.

Nussinov R, Zhang M, Maloney R, Tsai C, Yavuz B, Tuncbag N Med Res Rev. 2021; 42(2):770-799.

PMID: 34693559 PMC: 8837674. DOI: 10.1002/med.21863.


References
1.
Zhang X, Tang N, Hadden T, Rishi A . Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta. 2011; 1813(11):1978-86. DOI: 10.1016/j.bbamcr.2011.03.010. View

2.
Fowler T, Sen R, Roy A . Regulation of primary response genes. Mol Cell. 2011; 44(3):348-60. PMC: 3212756. DOI: 10.1016/j.molcel.2011.09.014. View

3.
Guldenhaupt J, Rudack T, Bachler P, Mann D, Triola G, Waldmann H . N-Ras forms dimers at POPC membranes. Biophys J. 2012; 103(7):1585-93. PMC: 3471449. DOI: 10.1016/j.bpj.2012.08.043. View

4.
Nussinov R, Muratcioglu S, Tsai C, Jang H, Gursoy A, Keskin O . The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas. Mol Cancer Res. 2015; 13(9):1265-73. PMC: 4572916. DOI: 10.1158/1541-7786.MCR-15-0165. View

5.
Whitmarsh A, Shore P, Sharrocks A, Davis R . Integration of MAP kinase signal transduction pathways at the serum response element. Science. 1995; 269(5222):403-7. DOI: 10.1126/science.7618106. View